The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.

Preliminary data suggest that the newly dubbed Omicron variant may be more infectious than previous versions of the virus, but it will take time to obtain the reliable data needed to answer pressing questions about its biology.

Health Canada has given the single COVID-19 shot the official greenlight for use in people 18 and older.

Researchers used sequencing data and phenotypic traits to predict which of 5,400 species were most likely to be susceptible to contracting and spreading the virus back to humans.

While the weather isn’t currently the dominant factor driving SARS-CoV-2 transmission, experts say that in the future COVID-19 may become a disease of winter.

Using a novel lab technique, researchers identified a mutation that allows the virus to insert more genetic material into host cells.

Multiple white tailed deer tested positive for SARS-CoV-2 likely transmitted from humans, a study finds, indicating the species could act as a reservoir for the virus.

With the final hurdle cleared, the COVID-19 vaccine could be administered to US children ages 5 through 11 as early as today.

It’s unclear whether differing odds of dying between men and women reflect inherent differences between male and female immune systems or differences rooted in gender norms.

Authors of a newly published study on the use of an antidepressant for COVID-19 claim the drug greatly reduces hospitalizations and mortality. But some experts question whether that’s really what the data show.

Preprints are likely here to stay. The press, the public, and the research community must adapt to this relatively recent model of scientific publishing if we are to extract its benefits while avoiding its pitfalls.

Preprints can be valuable additions to the scientific literature. But we must start seeing them as perishable commodities rather than akin to peer-reviewed, published studies.

Male placentas produce more proinflammatory molecules than female placentas, while people carrying male fetuses produce fewer antibodies in response to infection, a study finds.